# Boehringer Ingelheim Japan

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/boehringer-ingelheim-japan/

## Facts

| Field | Value |
| --- | --- |
| Country | JP |
| Description | company in Tokyo, Japan |
| OpenAlex ID | https://openalex.org/F4320317302 |
| ROR ID | https://ror.org/02r1d7x68 |
| Works | 1,488 |

## Funder papers

- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial](https://scholariq.org/papers/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified/)
- [Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)](https://scholariq.org/papers/double-blind-randomized-placebo-controlled-trial-evaluating-the-efficacy-and/)
- [ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors](https://scholariq.org/papers/araf-amplification-in-small-cell-lung-cancer-transformed-tumors-following/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.